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CPAP = continuous positive airways pressure; OSA = obstructive sleep apnea; SDB = sleep-disordered breathing.
Available online http://respiratory-research.com/content/2/6/315
Introduction
Our understanding of OSA has evolved from regarding it
as an interesting and occasionally annoying social curios-
ity to the recognition that OSA may act through various
mechanisms to increase morbidity and mortality [1]. The
health consequences of sleep apnea are especially
evident in the cardiovascular system, where it is becoming
increasingly apparent that untreated OSA may have direct
and deleterious effects on cardiac and vascular structure
and function. These effects may include subtle and sub-
clinical impairment of normal homeostatic regulation, such
as impaired baroreflex [2] and chemoreflex [3] functions,
and elevated nocturnal blood pressure, in sleep apnea
patients without any overt cardiovascular diseases. There
is also evidence that untreated OSA may possibly con-
tribute to the initiation and/or progression of pathophysio-
logic mechanisms involved in hypertension, heart failure,
cardiac ischemia and stroke. The evidence and mecha-
nisms linking OSA to vascular disease generally, and to
hypertension and stroke in particular, are outlined below.
OSA and hypertension
OSA appears to be highly prevalent in the middle-aged
general population, affecting 9% of females and 24% of
males between the ages of 30 and 60 years [4]. Hyper-
tension is also widespread in the middle-aged and older
populations. It is therefore likely that there would be con-
siderable co-morbidity of OSA and hypertension. Never-
theless, a number of studies suggest that the extent of this
co-morbidity is substantially greater than would be
expected in the absence of any causal interaction
between these disease conditions.
In studies in dogs, simulated sleep apnea (achieved by
intermittent and repetitive airway occlusion during sleep)
resulted in increased blood pressure during wakefulness
[5]. A number of studies in humans have sought to deter-
mine the presence and extent of a causal interaction
between OSA and hypertension, independent of fre-
quently co-existing, and potentially confounding, variables
common to both conditions (e.g. age, gender, body mass
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index, etc.). Davies et al. [6] performed a comparison of
24 hour ambulatory blood pressure profiles of 45
untreated patients with OSA and 45 control subjects
matched for the known confounding variables. Signifi-
cantly higher diastolic blood pressures during both the
night and day, and higher systolic blood pressures during
the night, were observed in the OSA patients.
The Sleep Heart Health Study, an observational and
cross-sectional investigation, examined the association
between sleep-disordered breathing (SDB) and resting
blood pressure in more than 6000 middle-aged and older
adults [7]. These data suggest that SDB was indepen-
dently associated with higher blood pressures. Specifi-
cally, the prevalence of hypertension (defined as a resting
blood pressure ≥140/90 mmHg or the use of antihyper-
tensive drugs) was found to progressively increase with
the severity of SDB. The interaction between blood pres-
sure and SDB was present even after adjusting for body
mass index, which predictably diminished the strength of
the association. Overall, the odds of hypertension
appeared to increase with increases in the apnea–hypop-
nea index in a dose–response fashion.
Similar data were evident from work by Bixler et al. in a
study of 1741 subjects [8]. They found the strength of the
association between SDB and hypertension varied with
age, and was most marked in the youngest individuals,
particularly those of normal weight.
Perhaps the most compelling etiologic evidence was pro-
vided recently by data from the Wisconsin Sleep Cohort
Study, which prospectively investigated the association
between SDB and the subsequent development of hyper-
tension at 4 years of follow-up [9]. The presence of SDB
at initial evaluation was accompanied by a substantially
increased risk for future hypertension. This relationship
was present even after adjusting for other potential con-
founding variables and exhibited a dose–response rela-
tionship. For subjects with an apnea–hypopnea index ≥15
events per hour, the risk ratio for developing new hyper-
tension over a period of 4 years was increased threefold
as compared with those without any nocturnal apnea.
Effective treatment of OSA may result in lower blood pres-
sure in hypertensive patients, particularly when blood
pressure is measured over 24 hours [10–12], hence
incorporating the effects of nocturnal blood pressure low-
ering. The blood pressure lowering effects of continuous
positive airways pressure (CPAP) therapy, especially for
daytime blood pressures, are less clear in normotensive
subjects, as will be discussed later.
OSA and stroke
An important earlier study from Palomaki et al. of 167 men
with stroke noted that about one third experienced their
strokes during sleep [13]. They further demonstrated that
only snoring was significantly related to stroke in sleep.
Palomaki subsequently reported that the odds ratio of
snoring as a risk factor for stroke was strongly increased if
snoring was accompanied by excessive obesity and
daytime somnolence [14]. Additional data supporting the
association between stroke and OSA have emerged since
these earlier studies [15]. Indeed, OSA has been impli-
cated as a risk factor for first stroke, recurrent stroke, and
post-stroke mortality.
Potential mechanisms mediating vasculopathy
in OSA patients
During sleep, repetitive episodes of airway occlusion, with
consequent hypoxemia, hypercapnia and dramatic
changes in intrathoracic pressure, elicit a wide variety of
autonomic, hemodynamic, humoral and neuroendocrine
responses. These responses themselves evoke acute
changes in cardiovascular function, as well as more sus-
tained effects that carry over into the daytime even when
breathing is normal. First, hypoxemia and hypercapnia
result in chemoreflex activation with consequent increases
in sympathetic vasoconstrictor traffic to peripheral blood
vessels [16] (Fig. 1). This reflex response results in striking
increases in blood pressure as well as increased levels of
circulating catecholamines. The sympathetic activity and
surges in blood pressure are markedly attenuated by
effective treatment with CPAP therapy [17]. Stradling et
al. reported that both nocturnal desaturations and respira-
tory effort (indirectly measured using pulse transit times)
were significant independent predictors of an increase in
blood pressure between night-time and morning [18].
While sympathetic activation is one mechanism that may
contribute to increased daytime blood pressures after
repetitive nocturnal apneas, a second possibility is the
pressor effect of endothelin [19]. Hypoxemia results in
increased levels of endothelin production [20]. Endothelin
is a potent vasoconstrictor. In untreated patients,
4–5 hours of repetitive nocturnal apneas results in signifi-
cant increases in both endothelin and blood pressure.
Treatment of the OSA over the subsequent 4 hours dra-
matically reduces both blood pressure and endothelin
levels when the subject is awake [21] (Fig. 2). Since
endothelin has sustained hypertensive effects that persist
for a number of hours, hypoxemia-mediated endothelin
release during sleep may result in sustained daytime blood
pressure elevation in patients with obstructive apnea.
A third potential contribution to vasculopathy in OSA is
endothelial dysfunction. The endothelial cells lining blood
vessels are the source of endothelin production. These
cells also produce a vasodilating substance, nitric oxide.
The ability of the endothelial cells to generate nitric oxide
in response to acetylcholine infusion provides an index of
endothelial function. Impaired endothelial function is char-c
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Figure 1
Recordings of sympathetic nerve activity (SNA), respiration (RESP) and intra-arterial blood pressure (BP) in the same subject when awake (top
left), with obstructive sleep apnea (OSA) during rapid eye movement (REM) sleep (bottom), and with elimination of obstructive apnea by
continuous positive airways pressure (CPAP) therapy during REM sleep (top right). SNA is very high during wakefulness, but increases even
further secondary to OSA during REM. BP increases from 130/65 mmHg when awake to 256/110 mmHg at the end of apnea. Overall, nocturnal
blood pressure is increased. Elimination of apnea by CPAP therapy (top right) results in decreased sympathetic traffic and prevents BP surges
during REM sleep. Reproduced with permission from [16].
Figure 2
Comparison of mean arterial pressure (MAP) and endothelin 1 (ET-1) in 22 patients with severe obstructive sleep apnea (OSA) before sleep at
approximately 22:00 hours, before nasal continuous positive airways pressure (CPAP) therapy at approximately 02:00 hours, and on waking at
approximately 07:00 hours after 5 hours of CPAP therapy. Measurements in control subjects without sleep apnea are shown on the right. Data are
means ± SEM. Reproduced with permission from [21].acteristic of hypertension [22] and atherosclerosis [23],
and may theoretically also result from the repetitive hypox-
emia and pressor surges evident in patients with OSA.
Indeed, in awake patients with OSA, in the absence of any
other disease state or potential cause for endothelial dys-
function, the endothelium-mediated vasodilator response
to intra-arterial acetylcholine was markedly impaired in
comparison with closely matched subjects without OSA
[24]. Subtle vascular abnormalities such as impaired
endothelial function in seemingly healthy patients with
OSA may thus predispose to the future development of
hypertension and vascular disease.
Other subclinical abnormalities in cardiovascular regula-
tion in OSA patients include derangements in cardiovas-
cular variability, a fourth possible mechanism for
cardiovascular disease in OSA. Seemingly healthy OSA
patients studied when awake and breathing normally in
the daytime have clear-cut decreases in heart rate variabil-
ity and increased blood pressure variability [25]. Heart
rate variability is markedly reduced in patients with heart
failure, and in patients after myocardial infarction [26,27].
Decreased heart rate variability in patients with idiopathic
dilated cardiomyopathy independently predicts the risk of
cardiac death or heart transplantation [28]. Depressed
heart rate variability after myocardial infarction is a power-
ful prognostic indicator for both arrhythmia and death [27].
Increased blood pressure variability in hypertension is
linked independently to target organ damage [29]. The
depressed heart rate variability and increased blood pres-
sure variability in patients with OSA, who appear to be
otherwise healthy and free of any overt cardiovascular
disease, may thus predispose to the future development of
clinically significant cardiovascular dysfunction.
Nocturnal blood pressure
Neural and humoral responses to night-time apnea result
in increases in night-time blood pressure. This response to
apnea may contribute in part to the phenomenon widely
described as ‘non-dipping’. Hypertensive patients whose
blood pressures either do not decline or actually increase
during the night appear to be at increased risk of cardiac
and vascular events in comparison with similarly hyperten-
sive patients whose blood pressures fall appropriately
during the night [30]. Undiagnosed OSA may contribute
to the absence of a nocturnal blood pressure fall, as a
consequence of the pressor effect of apnea.
In a randomized, placebo-controlled trial of CPAP therapy
in normotensive OSA patients, the greatest fall in blood
pressure was evident when patients were asleep, without
any substantial blood pressure reduction during wakeful-
ness [31]. These data are consistent with other studies in
normotensive patients, which showed no significant
change in daytime blood pressure after sustained CPAP
therapy [17]. Nevertheless, because even modest blood
pressure declines may be linked to significant improve-
ment in outcome, it is possible that some vascular benefit
can be gained from the nocturnal blood pressure reduc-
tion. Furthermore, subtle abnormalities in neural and
humoral measures of circulatory control in untreated sleep
apnea may conceivably be attenuated by effective therapy,
and the progression to overt cardiovascular disease may
be halted or slowed.
Conclusion
OSA is widely prevalent and is increasingly being linked to
cardiac and vascular disease. Even seemingly healthy
patients with OSA, without any evidence for overt cardio-
vascular disease, have subtle but very significant abnor-
malities in vascular regulation at several levels, including
the neural, humoral and endothelial levels. These abnor-
malities may act to overcome even redundant vasoprotec-
tive mechanisms, hence predisposing to the future
evolution of clinically significant functional and structural
vascular changes that may present as hypertension and/or
stroke. Effective treatment of OSA helps lower blood pres-
sure in hypertensive patients and may lower nocturnal
blood pressure in normotensive patients. These blood
pressure changes may themselves have significant benefi-
cial epidemiologic implications.
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